Leading Weight Loss Diabetes Drug Companies | Major Players 2026

Leading Weight Loss Diabetes Drug Companies

The following is a data-backed list of the leading Weight Loss Diabetes Drug companies, compiled through 6Wresearch's proprietary research and validated by in-house industry analysts. Novo Nordisk, Eli Lilly and Company and AstraZeneca currently lead the competitive landscape, alongside several other established players shaping the Global Weight Loss Diabetes Drug Market.

List of Weight Loss Diabetes Drug Companies:

1. Novo Nordisk

Novo Nordisk is a global pharmaceutical company specializing in diabetes and obesity treatments, including Wegovy, Ozempic and Rybelsus. Its metabolic-care portfolio is supported by extensive research, manufacturing and commercial operations.

2. Eli Lilly and Company

Eli Lilly is a top pharmaceutical company offering diabetes and obesity medicines such as Mounjaro and Zepbound, based on tirzepatide. The company manufactures and markets medicines internationally, with products sold in approximately 95 countries.

3. Roche

Roche is a major healthcare company developing metabolic and obesity therapies, including next-generation incretin-based candidates and partnered programs. Its pharmaceutical and diagnostics businesses operate.

4. Merck & Co./MSD

Merck is a leading science and technology company expanding into obesity and metabolic disease through licensed investigational therapies such as HS-10535, an oral GLP-1 receptor agonist.

5. AstraZeneca

AstraZeneca is a top biopharmaceutical company developing metabolic therapies, including oral GLP-1 medicines such as elecoglipron for obesity. Its research, development and manufacturing network supports pharmaceutical markets.

6. Pfizer

Pfizer is a major pharmaceutical company developing next-generation obesity and diabetes therapies, including investigational GLP-1 receptor agonists. Its extensive research and commercial infrastructure supports pharmaceutical activities.

7. Amgen

Amgen develops innovative biologic therapies for metabolic diseases, including maridebart cafraglutide (MariTide), an investigational obesity treatment targeting GLP-1 and GIP pathways.

8. Viking Therapeutics

Viking Therapeutics specializes in metabolic and endocrine therapies, representing its investigational obesity and weight-management candidate. The company focuses on developing novel therapies for metabolic disorders and advancing them.

9. Innovent Biologics

Innovent Biologics is a Chinese biopharmaceutical company developing metabolic treatments, including mazdutide, a GLP-1/glucagon receptor dual agonist for obesity and type 2 diabetes.

10. Zealand Pharma

Zealand Pharma specializes in peptide-based medicines for metabolic diseases, with candidates including petrelintide and survodutide targeting obesity and related metabolic conditions.

11. Boehringer Ingelheim

Boehringer Ingelheim develops metabolic medicines for obesity and related conditions, including survodutide, a GLP-1/glucagon dual agonist developed with Zealand Pharma. Its research and commercial activities span major pharmaceutical markets worldwide.

Frequently Asked Questions About the Market Study (FAQs):